J. Goldman & Co LP Buys Shares of 112,129 Enliven Therapeutics, Inc. $ELVN

Key Points

• J. Goldman & Co. LP acquired 112,129 Enliven Therapeutics shares worth approximately $5.7 million in the second quarter, while institutional investors collectively own 95.08% of ELVN.
• ELVN was trading near its 12-month high at $61.01, after reporting a quarterly loss of $0.49 per share that missed analyst expectations of a $0.39 loss.
• Analyst sentiment remains broadly positive, with eight Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and a $75 average price target; insiders, however, sold $11.3 million of shares over the past 90 days.

J. Goldman & Co LP bought a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 112,129 shares of the company's stock, valued at approximately $5,691,000. J. Goldman & Co LP owned about 0.15% of Enliven Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. ADAR1 Capital Management LLC bought a new position in Enliven Therapeutics during the 2nd quarter valued at $19,677,000. Canada Pension Plan Investment Board bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $782,000. Nicholas Investment Partners LP bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $19,870,000. Legal & General Group Plc bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $1,671,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $3,820,000. Institutional investors own 95.08% of the company's stock.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44. Following the transaction, the chief financial officer owned 40,036 shares of the company's stock, valued at approximately $2,345,308.88. This trade represents a 13.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business's stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the sale, the director owned 41,884 shares in the company, valued at $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 196,849 shares of company stock valued at $11,344,257 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

Enliven Therapeutics Price Performance

ELVN opened at $61.01 on Wednesday. The stock's 50 day moving average price is $53.73 and its 200 day moving average price is $42.53. The stock has a market cap of $4.47 billion, a P/E ratio of -36.53 and a beta of 0.27. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on ELVN. Wall Street Zen cut Enliven Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Barclays started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They issued an "overweight" rating and a $78.00 price target for the company. Mizuho upped their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a research report on Tuesday, August 18th. HC Wainwright increased their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Thursday, July 9th. Finally, William Blair began coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They issued an "outperform" rating on the stock. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $75.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source